A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease

Jagpal Singh Klair, Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine Yates, Aynur Unalp‐Arida, Joel E. Lavine, Jeanne M. Clark, Anna Mae Diehl, Ayako Suzuki, for the Nonalcoholic Steatohepatitis Clinical Research Network – 26 February 2016 – Postmenopausal women with nonalcoholic steatohepatitis are at an increased risk of hepatic fibrosis compared with premenopausal women. Whether duration of estrogen deficiency in postmenopausal state dictates an individual's fibrosis risk remains uninvestigated.

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation

Neil E. Crittenden, Laura A. Buchanan, Christina M. Pinkston, Barbra Cave, Ashutosh Barve, Luis Marsano, Craig James McClain, Christopher M. Jones, Michael R. Marvin, Eric G. Davis, Candice B. Kuns‐Adkins, Roberto Gedaly, Guy Brock, Malay B. Shah, Jens Rosenau, Matthew C. Cave – 25 February 2016 – Although combination simeprevir (SIM) plus sofosbuvir (SOF) is an approved regimen for genotype 1 chronic hepatitis C virus (HCV), data regarding its safety and efficacy in liver transplant recipients remain limited.

Subscribe to